%0 Generic
%A Gettinger, S.
%A Borghaei, H.
%A Brahmer, J.
%A Chow, L.
%A Burgio, M.
%A De Castro Carpeno, J.
%A Pluzanski, A.
%A Arrieta, O.
%A Aren Frontera, O.
%A Chiari, R.
%A Butts, C.
%A Wojcik-Tomaszewska, J.
%A Coudert, B.
%A Garassino, M.
%A Ready, N.
%A Felip, E.
%A Alonso Garcia, M.
%A Waterhouse, D.
%A Domine, M.
%A Barlesi, F.
%A Antonia, S.
%A Wohlleber, M.
%A Gerber, D.
%A Czyzewicz, G.
%A Spigel, D.
%A Crino, L.
%A Eberhardt, W.
%A Li, A.
%A Marimuthu, S.
%A Vokes, E.
%T Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC
%D 2019
%@ 1556-0864
%U https://hdl.handle.net/10668/27253
%K nivolumab
%K 5-year overall survival
%K advanced non-small cell lung cancer
%~